A single intravenous infusion is now capable of freeing people with Hemophilia B from a lifetime of routine clotting factor injections. Hemgenix, the first FDA-approved gene therapy for the condition, delivers a functional copy of the Factor IX gene directly into the body, and clinical data from the pivotal HOPE-B trial showed that 96 percent of patients were able to stop their regular prophylactic injections within 18 months of that one-time treatment. For the estimated 30,000 people living with Hemophilia B worldwide, many of whom have spent decades tethering their lives to weekly or biweekly infusions, this represents a fundamental shift in what treatment looks like. The story behind this breakthrough, however, is more complicated than a single headline suggests.
While Hemgenix remains commercially available as of 2026, a second gene therapy called Beqvez was approved by the FDA in April 2024 only to be withdrawn by Pfizer less than a year later after zero patients received it post-approval. The therapy carries a price tag of $3.5 million, making it the most expensive drug in the world, and adoption has been slower than many in the field anticipated. This article examines how the therapy works, what the long-term safety data actually shows after more than a decade of follow-up, who qualifies, what the cost debate looks like, and why a treatment that genuinely works is still struggling to reach the patients who need it. For readers following developments in brain health and neurological research, the gene therapy advances in hemophilia offer a useful lens into how single-dose genetic treatments may eventually be applied to neurological conditions, including certain forms of dementia linked to single-gene mutations.
Table of Contents
- How Does Gene Therapy for Hemophilia B Eliminate the Need for Factor IX Injections?
- What the Longest Safety Data in Hemophilia Gene Therapy History Tells Us
- The $3.5 Million Question and the Economics of a One-Time Cure
- Who Qualifies for Hemophilia B Gene Therapy and Who Does Not
- Why a Breakthrough Therapy Is Struggling to Reach Patients
- Lessons for Brain Health and Neurological Gene Therapy Research
- What Comes Next for Hemophilia Gene Therapy and Beyond
- Conclusion
- Frequently Asked Questions
How Does Gene Therapy for Hemophilia B Eliminate the Need for Factor IX Injections?
Hemophilia B is caused by mutations in the gene responsible for producing Factor IX, a protein essential for blood clotting. Without adequate Factor IX, even minor injuries can lead to prolonged bleeding, and spontaneous bleeds into joints and muscles are a constant threat. Traditional management requires patients to inject themselves with replacement Factor IX on a regular schedule, typically once or twice per week, for life. It is effective but burdensome, and it does nothing to address the underlying genetic deficiency. Gene therapy takes a fundamentally different approach. Both Hemgenix and the now-withdrawn Beqvez used an adeno-associated virus (AAV) vector to carry a functional copy of the Factor IX gene into the patient’s liver cells, where Factor IX is naturally produced.
The treatment is administered as a single one-time IV infusion. Once the gene is delivered, the liver begins producing its own Factor IX, potentially for years or even decades. In the HOPE-B trial that led to Hemgenix’s approval, patients achieved mean Factor IX activity levels of 39 percent at six months, which settled to 36.1 percent through five years post-infusion. While this is below the normal range of 50 to 150 percent, levels above 5 percent are generally sufficient to prevent most spontaneous bleeds. To put this in practical terms, consider a patient who has been injecting Factor IX concentrate every Tuesday and Friday for 20 years. After one infusion of Hemgenix, that patient has a strong probability of setting aside those syringes entirely. The annualized bleeding rate among trial participants dropped by 63 percent through five years, and most patients maintained adequate protection without returning to prophylaxis.
What the Longest Safety Data in Hemophilia Gene Therapy History Tells Us
Any gene therapy raises legitimate questions about what happens years or decades after the viral vector delivers its payload. In the case of Hemophilia B gene therapy, we now have an unusually long window of real-world data. A 13-year follow-up study conducted by St. Jude Children’s research Hospital and University College London, published in 2025, tracked 10 adults with severe Hemophilia B who received an early AAV-based gene therapy. The results showed stable Factor IX levels and no toxic side effects over the entire 13-year period, making it the longest safety dataset for any hemophilia gene therapy to date. This is reassuring, but it comes with important caveats.
The cohort was small, just 10 patients, and the specific vector and dose used in that early trial differ from what is now commercially available as Hemgenix. The HOPE-B trial data for Hemgenix itself extends to five years, with clinical evidence suggesting the single dose may provide adequate protection from uncontrolled bleeding for at least eight years and potentially longer. However, “potentially longer” is not a guarantee. Factor IX levels do decline modestly over time, from 39 percent at six months to 36.1 percent at five years, and no one yet knows with certainty whether a second treatment might eventually be needed. If you or a family member are evaluating this therapy, the honest answer is that the safety profile over 13 years is encouraging and the five-year efficacy data is strong, but lifetime durability remains an open question. This uncertainty is one of the key reasons adoption has been slower than expected.
The $3.5 Million Question and the Economics of a One-Time Cure
Hemgenix is priced at $3.5 million for a single treatment, making it the most expensive drug in the world. That number tends to dominate any conversation about the therapy, and understandably so. But the economics of hemophilia treatment are unusual in ways that make the sticker price less straightforward than it appears. Prophylactic Factor IX replacement therapy is itself extraordinarily expensive. Depending on severity and the specific product used, lifetime treatment costs for a single patient can run well above $5 million.
CSL Behring, the manufacturer of Hemgenix, argues that the one-time gene therapy could save the U.S. healthcare system between $5 million and $5.8 million per patient over a lifetime compared to ongoing prophylaxis. The Institute for Clinical and Economic Review, an independent body that assesses drug pricing, conducted its own analysis and determined that a fair price for Hemgenix would be up to $2.9 million, suggesting the current price is above what the clinical evidence supports but not wildly out of line with the value it delivers. The practical challenge is that insurance systems and healthcare budgets are not designed to absorb a $3.5 million charge in a single year, even if it saves money over decades. Several insurers have begun offering outcomes-based contracts, where payment is tied to whether the therapy continues working over a defined period. This model is still in its early stages, and many patients and their physicians remain uncertain about whether they will actually be able to access the therapy through their existing coverage.
Who Qualifies for Hemophilia B Gene Therapy and Who Does Not
Gene therapy for Hemophilia B is not available to everyone with the condition. The current FDA approval limits Hemgenix to adults aged 18 and older with moderately severe to severe Hemophilia B. Pediatric patients are excluded, which is significant because hemophilia is typically diagnosed in early childhood and the burden of lifelong prophylaxis falls most heavily on younger patients and their families. Clinical trials in children have not yet advanced to the point where regulatory approval is possible, though research is ongoing. There is a second eligibility barrier that is less well known but equally important.
Patients who have pre-existing antibodies to the AAV5 viral vector used to deliver the gene cannot receive the therapy. AAV5 is a common virus, and a substantial portion of the population has been exposed to it naturally, producing antibodies that would neutralize the therapy before it could work. Screening for these antibodies is a required step before treatment, and patients who test positive are currently excluded. For someone considering gene therapy, the practical steps are clear: speak with a hematologist at a hemophilia treatment center, undergo AAV5 antibody screening, and have a detailed conversation about the trade-offs between the known efficacy of current prophylaxis and the promise but uncertainty of a one-time treatment. This is not a decision to make quickly or based on headlines alone.
Why a Breakthrough Therapy Is Struggling to Reach Patients
The story of Beqvez is perhaps the most striking illustration of the challenges facing hemophilia gene therapy. Pfizer’s product received FDA approval in April 2024 after demonstrating solid clinical results. Less than a year later, in February 2025, Pfizer halted production and withdrew the therapy globally. The reason was not a safety concern but something arguably more troubling for the field: zero patients received Beqvez after its approval. The EU marketing authorization was subsequently withdrawn on May 15, 2025. The failure of Beqvez to attract a single commercial patient reflects several converging factors.
The $3.5 million price point creates sticker shock for payers and institutions. The uncertainty about how long the therapy’s effects will last makes both patients and their physicians cautious. And critically, current prophylactic regimens, while burdensome, are effective and well-understood. Patients who have managed their condition for years with regular injections may be understandably reluctant to undergo an irreversible gene therapy when the long-term outcomes remain uncertain and there is currently no option to repeat the treatment if the effects fade. This is a warning worth heeding for anyone watching the gene therapy space broadly, including those hopeful about future applications in neurology and dementia. A therapy can be scientifically sound and clinically effective and still fail in the marketplace if the price, the delivery infrastructure, and patient confidence are not aligned.
Lessons for Brain Health and Neurological Gene Therapy Research
The parallels between hemophilia gene therapy and emerging neurological treatments are worth noting. Several forms of early-onset dementia and neurodegenerative disease are linked to specific genetic mutations, and AAV-based gene therapies are in various stages of development for conditions including certain lysosomal storage diseases that cause neurodegeneration. The hemophilia experience offers a real-world case study in what works, what doesn’t, and what obstacles sit between a promising clinical trial and a treatment that actually reaches patients.
The 13-year safety data from St. Jude is particularly relevant for neurological applications, where the consequences of a delayed adverse event in the brain would be far more serious than in the liver. The hemophilia data provides a growing evidence base that AAV vectors can remain stable in human tissue for well over a decade without causing significant toxicity, a finding that will inform the risk-benefit calculations for gene therapies targeting the central nervous system.
What Comes Next for Hemophilia Gene Therapy and Beyond
The field is not standing still. Researchers are working on next-generation AAV vectors that might evade pre-existing antibodies, potentially opening the door to patients currently excluded from treatment. Efforts are also underway to develop gene therapies that could be administered to children, which would fundamentally change the natural history of hemophilia by intervening before decades of joint damage and treatment burden accumulate.
The commercial struggles of the first generation of hemophilia gene therapies will likely reshape how future products are priced, insured, and delivered. Outcomes-based payment models, gene therapy-specific insurance products, and international pricing agreements are all being explored. For patients with Hemophilia B today, Hemgenix remains a viable and powerful option. For the broader field of genetic medicine, including those working on neurological conditions, the lessons being learned right now in hemophilia will echo for years to come.
Conclusion
Gene therapy for Hemophilia B has moved from theoretical promise to clinical reality. Hemgenix offers a genuine, single-dose alternative to lifelong injections, backed by five years of efficacy data showing sustained Factor IX production, a 63 percent reduction in bleeding events, and 96 percent of trial participants discontinuing prophylaxis. The 13-year safety follow-up from St. Jude provides the longest evidence base of any hemophilia gene therapy and shows no toxic side effects. These are not modest results.
Yet the path from clinical success to widespread patient impact remains unfinished. The $3.5 million price, uncertainty about lifetime durability, eligibility restrictions excluding children and patients with AAV5 antibodies, and the cautious conservatism of patients who already manage their condition effectively have all slowed adoption. The withdrawal of Beqvez after zero commercial patients is a sobering reminder that transformative science alone does not guarantee transformative access. For patients considering gene therapy, the conversation with a specialist hematologist is the essential next step. For those watching the broader trajectory of genetic medicine in neurology and beyond, hemophilia gene therapy is the proving ground, and its successes and struggles are writing the playbook.
Frequently Asked Questions
Is Hemgenix a permanent cure for Hemophilia B?
Hemgenix is not described as a permanent cure. Clinical data shows sustained Factor IX activity through five years, with evidence suggesting protection for at least eight years. However, Factor IX levels do decline modestly over time, and whether the treatment provides lifelong protection is not yet known. It is currently not possible to repeat the treatment.
Why was Beqvez withdrawn if it was FDA-approved?
Pfizer withdrew Beqvez in February 2025 because zero patients received the therapy after its April 2024 approval. The withdrawal was driven by lack of uptake from patients and clinicians, not by safety problems. Concerns about the high price, long-term durability uncertainty, and satisfaction with existing prophylaxis all contributed.
Can children with Hemophilia B receive gene therapy?
No. Both Hemgenix and the now-withdrawn Beqvez were approved only for adults aged 18 and older. Clinical trials for pediatric patients are in earlier stages of development and have not yet led to regulatory approval.
How much does Hemgenix cost and does insurance cover it?
Hemgenix is priced at $3.5 million for a single infusion, the highest price for any drug in the world. Some insurers are beginning to offer outcomes-based contracts, but coverage varies significantly. The independent Institute for Clinical and Economic Review assessed a fair price of up to $2.9 million, suggesting the current price exceeds their value threshold.
What disqualifies someone from receiving Hemgenix?
Patients must be adults with moderately severe to severe Hemophilia B. Those who have pre-existing antibodies to the AAV5 viral vector are ineligible because their immune system would neutralize the therapy. Antibody screening is required before treatment.
Does gene therapy for hemophilia have implications for dementia treatment?
The AAV vector technology used in hemophilia gene therapy is being explored for several neurological conditions, including certain genetic forms of neurodegeneration. The 13-year safety data from hemophilia trials is particularly valuable for neurological applications, where long-term vector stability in human tissue is a critical safety question.
